Gastrointestinal stromal tumors (GIST) lacking mutations in KIT/PDGFRA or RAS pathways and retaining an intact SDH complex are usually referred to as KIT/PDGFRA/SDH/RAS-P WT GIST or more simply quadruple WT GIST (~5% of all GIST). Despite efforts made, no recurrent genetic event in quadruple WT GIST has been identified so far. To further investigate this disease, we performed high throughput copy number analysis on quadruple WT GIST specimens identifying a recurrent focal gain in band 11q13.3 (involving FGF3/FGF4) in 6/8 cases. This event was not found in the other molecular GIST subgroups. FGF3/FGF4 duplication was associated with high expression of FGF4, both at mRNA and protein level, a growth factor normally not expressed in adult tissues or in KIT/PDGFRA-mutated GIST. FGFR1 was found to be the predominant FGF receptor expressed and phosphorylation of AKT was detected, suggesting that a FGF4-FGFR1 autocrine loop could stimulate downstream signaling in quadruple WT GIST. Together with the recent reports of quadruple WT cases carrying FGFR1 activating alterations, these findings strengthen the hypothesis of a potential involvement of FGFR pathway deregulation in quadruple WT GIST, which may represent a rationale for novel therapeutic approaches. 
| INTRODUCTION

Gastrointestinal stromal tumors (GIST) not harboring mutations in
KIT or platelet-derived growth factor receptor alpha (PDGFRA) receptors (~10%-15% of adult cases) are often referred to as KIT/PDGFRA wild-type (WT) GIST. 1 Between 20% and 40% of KIT/PDGFRA WT GIST show loss of function of the succinate dehydrogenase complex (SDH), designated as SDH-deficient GIST, recognized by the loss of subunit B (SDHB) protein expression. [2] [3] [4] Moreover, another subgroup (~15% of KIT/PDGFRA WT GIST) harbours mutations in BRAF/RAS or NF1 and are referred to as RASpathway (RAS-P) mutant GIST. [5] [6] [7] The remaining cases, lacking mutations in the KIT/PDGFRA or RAS pathways, and retaining an intact SDH complex, are usually referred to as KIT/PDGFRA/SDH/ RAS-P WT GIST or more simply quadruple WT GIST, accounting approximately for 50% of KIT/PDGFRA WT GIST and 5% of all GIST. 8 These cases show a transcriptome profile that profoundly differs from KIT/PDGFRA-and SDHA-, or possibly all SDH-mutant GIST, indicating that quadruple WT GIST could represent another unique group within the family of GIST. 9, 10 Recently, despite the homogenous transcriptome profile, the extensive molecular characterization of quadruple WT GIST failed to detect any recurrent genetic event underlying the disease, conversely providing evidence of a great molecular heterogeneity, with many different and sometimes private mutational events such as fusion genes involving ETV6-NTRK3 or FGFR1 and mutations on FGFR1, TP53, MAX, and MEN1. [10] [11] [12] [13] However, whether these alterations were driver or secondary events is still to be proven, even if the heterogeneity of the mutated genes and the lack of any recurrent genetic feature supports the view that the underlying shared pathway of quadruple WT GIST is still to be uncovered. In this study, a deep molecular analysis was performed to further investigate the biological background of this very rare subgroup of disease that extensively differs from other GIST.
| MATERIALS AND METHODS
| Patients and tumor samples
Tissue samples of eight quadruple WT, five fresh frozen (FF), and three formalin-fixed paraffin-embedded (FFPE), being negative for mutations in KIT, PDGFRA, SDHx, and RAS-P genes, were centralized at "Giorgio Prodi" Cancer Research Center (CIRC), University of Bologna, within a multicentric collaborative project. Patients and tumor characteristics are listed in Table 1 . GIST diagnosis was based on histologic evaluation and on immunohistochemistry of CD117 and DOG1 and was centrally reviewed. In addition to Sanger sequencing performed at the time of diagnosis, the mutational status of KIT, PDGFRA, BRAF, KRAS, SDHx, and NF1 was evaluated through a custom amplicon sequencing panel using Truseq Custom
Amplicon low input kit (Illumina). Moreover, SDH deficiency was excluded by IHC of SDHB. Seven out of these eight quadruple WT cases were also analyzed through whole exome sequencing in a previously published article 10 and relevant alterations were reported in four cases: a truncating mutation of CTNND2 in GIST127, a homozygous frameshift deletion of MEN1 and TP53 mutation in GIST320, a frameshift deletion on MAX combined with a germline variant on NF1 (p.R2573L) in GIST268, an activating mutation (p.N546K) of FGFR1 in GIST409 (Table 1) . 
| Copy number Taqman assays
Validation of FGF4 copy number state was performed on FF quadruple DDCt method, using GAPDH as housekeeping gene. Primer used were: 3 | RESULTS
| qRT-PCR
FGF4_Fw 5 0 -CCAGCCGGTTCTTCGTG-3 0 ; FGF4_Rev 5 0 -ATCGGTGAA GAAGGGCGAG-3 0 ; GAPDH_Fw 5 0 -CGGGAAGCTTGTCATCAAT-3 0 and GAPDH_Rev 5 0 -GACTCCACGACGTACTCAGC-3 0 .
| Western blot
| FGF3/FGF4 locus is recurrently duplicated in quadruple WT GIST
High throughput copy number analysis was performed in eight quadruple WT GIST, highlighting the presence of a recurrent focal gain of one copy in chromosome 11q13.3 cytoband in six samples. The cryptic copy number gain detected overlapped the FGF3/FGF4 locus, and was present either in tumors with a normal disomic chromosome 11 (Sample GIST400, 401, 133, and 219) and in two other cases (GIST127 and 320), that showed complete loss of the q-arm of chromosome 11 ( Figure 1A ).
In addition GIST127 showed a complex copy number state in the region spanning 11q with the presence of the intrachromosomal rearrangements MARK2-PPFIA1 and PLA2G16-ATL3, involving genes located in close proximity of the 11q13.3 copy number gain ( Figure 1B) . Conversely, the two cases without 11q13.3 focal gain were known to carry putative pathogenetic alterations (Table 1) , since GIST268 harboured a germline rare variant on NF1 and a somatic frameshift deletion on MAX and GIST409
carried an activating mutation (p.N546K) of FGFR1.
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Quantitative PCR on the FGF4 region was employed to validate the copy number gain in FF quadruple WT, confirming the presence of the focal duplication of FGF4 in the four previously identified cases (GIST127, GIST133, GIST400, GIST401) while, as expected, GIST409
did not show the FGF4 copy number gain ( Figure 1C ). GIST133, a quadruple WT GIST, was found positive for FGF3/FGF4 gain using both CytoScan HD and SNP6.0 arrays, confirming the sensibility of both array types to detect the cryptic gain (data not shown). Figure 2C ). GIST409, similarly to KIT-mutant GIST, did not express FGF4 protein ( Figure 2C ).
We then investigated whether FGF4 could activate its downstream signaling. Interestingly, while KIT phosphorylation was not detected in quadruple WT GIST, phosphorylation of AKT was detected also in quadruple WT GIST, suggesting the presence of a FGF4/FGFR1 autocrine loop that activates downstream signaling in this subgroup ( Figure 2D ). 
| DISCUSSION
In the present study we discovered the presence of a recurrent focal copy number gain encompassing the FGF3/FGF4 locus specifically in quadruple WT GIST, which was associated with a high expression of FGF4. Fibroblast growth factor 4 has a key role in maintaining the self-renewal potential of normal stem cells 16 and it is usually not expressed in human adult tissues (with the exception of testis). 17 It was firstly identified as an oncogene in gastric cancer and Kaposi's sarcoma 18, 19 and it has been found overexpressed in several malignancies (including germ cell tumors, ovarian cancer, hepatocellular carcinoma, and lung adenocarcinoma), generally associated with aggressiveness and poorer prognosis. 17, [20] [21] [22] In our cases, the cryptic duplication of FGF3/ FGF4 was predominantly found in tumors with a normal disomic chromosome 11, however, it was detected also in cases showing the complete loss of one of the two copies of the q-arm of the chromosome.
Both genes are located in the 11q13 cytoband, and together with FGF19, EMS1, and CCND1 are frequently amplified in solid cancers including breast cancer, squamous cell carcinoma, esophageal cancer, bladder cancer, and hepatocellular carcinoma. [23] [24] [25] [26] [27] Interestingly, through in vitro and in vivo studies in hepatocellular carcinoma, FGF3/FGF4 focal amplification was demonstrated to be related to FGF3 and FGF4 overexpression and to an increased sensitivity to sorafenib. 21 Noticeably, while FGF4 was absent or slightly expressed in KIT/PDGFRA/SDH-mutated GIST, it was found highly expressed in quadruple WT GIST, supporting a causal role of the gain in the transcriptional activation of the gene. On the other hand, no significant upregulation of FGF3 was detected, indicating that this gene may not be the biologicallyrelevant pathogenic event. The mechanism for which the duplication N546K activating mutation in the other. 10 In previous works, quadruple WT GIST have been shown to carry a homogeneous signature profile, 9,10 however, no recurrent genetic alteration has been detected so far. 13 Interestingly, among the alterations identified, three different events affecting FGFR1 were detected: FGFR1 p.N546K mutation 10, 11 and FGFR1-HOOK3 and FGFR1-TACC1 fusion genes. GIST. 32, 33 In our series, no patient had received treatment with FGFR inhibitors.
Due to the small number of cases and the clinical heterogeneity, we cannot postulate any definitive consideration regarding the prognostic or predictive significance or clinical association of FGF3/FGF4 duplication from our series. In fact, in localized cases risk of recurrence ranged from very low to high, while the two metastatic cases did not receive regorafenib. There was no gender or age predominance in patients. The only interesting clinical data were that all quadruple WT cases developed GIST in the small bowel and did not present lymph nodes metastases, as these occur mostly in SDH-deficient GIST.
In conclusion, for the first time a recurrent event shared by quadruple WT GIST is reported in this study, even if these findings should be tested and confirmed in larger series. Gain of FGF4, together with FGFR1 mutations, represents the most frequent molecular alteration identified in this subgroup so far, suggesting that these specific driver events could aid the diagnostic process of KIT/PDGFRA/SDH/RAS-P WT GIST, that are currently still diagnosed only by exclusion, and, most important, that FGFR pathway activation could provide a rationale for targeted therapeutic approaches.
